Update on Sparsentan Development in Rare Kidney Diseases
Time: 3:30 pm
day: Day Two
Details:
- Summarizing available information from ongoing clinical trials with sparsentan in patients with IgA nephropathy and FSGS
- Exploring data in parallel with supporting preclinical evidence
- Navigating next steps in clinical development and beyond orphan drug designation
